Healthcare Industry News: QIAGEN
News Release - August 12, 2010
Radient Pharmaceuticals Appoints Gary Giarratano as Director of North American Sales and MarketingTUSTIN, CA--(Healthcare Sales & Marketing Network) - Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC ) announced today the appointment of Gary Giarratano as Director of North American Sales and Marketing, responsible for managing the company's sales and marketing strategy, operations and Onko-SureŽ in vitro diagnostic (IVD) product sales for North America.
Armed with a tenured track record of success in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to RPC. He is recognized for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays. Throughout his career, Giarratano has thrived in a variety of sales positions with both established and emerging healthcare and pharmaceutical companies that include QIAGEN, Roche Diagnostics, AutoGenomics Inc., Sebia Inc., Esoterix Laboratory, PerkinElmer Life Sciences and Hybritech Inc. While each opportunity offered new challenges, Giarratano's top priorities consistently focused on advancing corporate growth and market share through effective and profitable sales planning, management and program execution.
"Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure," said Douglas MacLellan, Chairman and CEO of RPC. "Giarratano has demonstrated talent in strategically aligning sales objectives with marketplace demands, and meeting those demands through proven sales performance. His wealth of expertise in the IVD industry combined with a proven ability to deliver results makes him an exceptional leader we believe will help propel sales of Onko-Sure to the next level."
Giarratano has deep professional industry affiliations with major healthcare companies that include: Quest, Lab Corp., Mayo, Kaiser, MetroPath, UniPath, Summit Pathology, TriCore, Intermountain Health Care and other regional reference labs. Giarratano received his Bachelor of Science degree in Biology from the University of Southern Colorado and completed graduate work in Coral Reef Ecology at Fairleigh Dickinson University, West Indies Laboratory Christianstead, St. Croix, US Virgin Islands. He also received his secondary education teaching certificate from the Metropolitan State College in Denver, Colorado.
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-SureŽ In Vitro Diagnostic cancer test. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical's current Onko-SureŽ cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Source: Radient Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.